Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433498 | 0.89 | PTPRA (0.33) | PTPRA | |
| SCHEMBL9555112 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL9555107 | 0.82 | PPARG (0.39) | — | |
| SCHEMBL16452409 | 0.81 | PTPRA (0.34) | PTPRA | |
| SCHEMBL3670921 | 0.81 | APAF1 (0.40) | PTPRA | |
| SCHEMBL6865358 | 0.81 | MAP3K7 (0.30) | — | |
| SCHEMBL3159235 | 0.81 | APAF1 (0.40) | PTPRA | |
| SCHEMBL12202544 | 0.81 | MAP3K7 (0.30) | — | |
| SCHEMBL8255199 | 0.81 | PTPRA (0.34) | PTPRA | |
| SCHEMBL3156583 | 0.81 | APAF1 (0.40) | PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217022-B2 | GLP-1 receptor agonist compounds having stabilized regions | ASTRAZENECA PHARMACEUTICALS LP (US) | 2015-12-22 | — | — | US | disclosed |
| US-8642544-B2 | N-terminus conformationally constrained GLP-1 receptor agonist compounds | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120046222-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184203-A1 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | GLP1R, GIPR, GCGR | PTPRA 2268/4885 |
| US-20120046222-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | PTPRA 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.